ASYMCHEM LAB.(TIAN.)H YC1 (7K90) - Total Liabilities
Based on the latest financial reports, ASYMCHEM LAB.(TIAN.)H YC1 (7K90) has total liabilities worth €2.74 Billion EUR (≈ $3.21 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ASYMCHEM LAB.(TIAN.)H YC1 (7K90) net asset momentum to track the company's year-over-year net asset growth rate.
ASYMCHEM LAB.(TIAN.)H YC1 - Total Liabilities Trend (2021–2025)
This chart illustrates how ASYMCHEM LAB.(TIAN.)H YC1's total liabilities have evolved over time, based on quarterly financial data.
ASYMCHEM LAB.(TIAN.)H YC1 Competitors by Total Liabilities
The table below lists competitors of ASYMCHEM LAB.(TIAN.)H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PCB Bancorp
NASDAQ:PCB
|
USA | $2.89 Billion |
|
Alliance Entertainment Holding Corporation Class A Common Stock
NASDAQ:AENT
|
USA | $316.48 Million |
|
LINKBANCORP Inc
NASDAQ:LNKB
|
USA | $2.76 Billion |
|
Jiangsu Hongde Special Parts Co.Ltd.
SHE:301163
|
China | CN¥372.77 Million |
|
Galata Wind Enerji Anonim Sirket
IS:GWIND
|
Turkey | TL5.36 Billion |
|
Claros Mortgage Trust Inc
NYSE:CMTG
|
USA | $3.69 Billion |
|
RMR Group Inc
NASDAQ:RMR
|
USA | $280.18 Million |
|
Northeast Community Bancorp Inc
NASDAQ:NECB
|
USA | $1.71 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ASYMCHEM LAB.(TIAN.)H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ASYMCHEM LAB.(TIAN.)H YC1 (7K90) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ASYMCHEM LAB.(TIAN.)H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ASYMCHEM LAB.(TIAN.)H YC1 (2021–2025)
The table below shows the annual total liabilities of ASYMCHEM LAB.(TIAN.)H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.63 Billion ≈ $3.08 Billion |
+8.46% |
| 2024-12-31 | €2.43 Billion ≈ $2.84 Billion |
+7.48% |
| 2023-12-31 | €2.26 Billion ≈ $2.64 Billion |
-11.28% |
| 2022-12-31 | €2.54 Billion ≈ $2.97 Billion |
-0.08% |
| 2021-12-31 | €2.55 Billion ≈ $2.98 Billion |
-- |
About ASYMCHEM LAB.(TIAN.)H YC1
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more